EP2090307A1 — Pharmaceutical composition for the treatment or prevention of osteoarticular diseases
Assigned to Bone Therapeutics SA · Expires 2009-08-19 · 17y expired
What this patent protects
The present invention is related to a pharmaceutical composition for the acute and/or chronic treatment (or prevention) of osteoarticular diseases, comprising - possibly an adequate pharmaceutical carrier or diluent - a polysaccharide and/or a glycosaminoglycan - a compound ac…
USPTO Abstract
The present invention is related to a pharmaceutical composition for the acute and/or chronic treatment (or prevention) of osteoarticular diseases, comprising - possibly an adequate pharmaceutical carrier or diluent - a polysaccharide and/or a glycosaminoglycan - a compound activating the alpha 2 adrenergic receptor - an anti-inflammatory agent and stem cells.
Drugs covered by this patent
- Alphagan (BRIMONIDINE TARTRATE) · Senju Pharmaceutical Co., Ltd
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.